Prograf and Type 1 diabetes - a phase IV clinical study of FDA data

Summary:

Type 1 diabetes is reported as a side effect among people who take Prograf (tacrolimus), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Cellcept, and have Chronic renal failure.

The phase IV clinical study analyzes which people have Type 1 diabetes when taking Prograf. It is created by eHealthMe based on reports of 41,725 people who have side effects when taking Prograf from the FDA, and is updated regularly.

What is Prograf?

Prograf has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 42,230 Prograf users. Check the latest studies of Prograf.

What is Type 1 diabetes?

Type 1 diabetes is found to be associated with 668 drugs and 1,644 conditions by eHealthMe. Check the latest studies of Type 1 diabetes.

On Jul, 13, 2026

41,725 people reported to have side effects when taking Prograf.
Among them, 51 people (0.12%) have Type 1 diabetes.

Among these 51 people:

How long have people been on Prograf when they have Type 1 diabetes? *

What is the gender of people who have Type 1 diabetes when taking Prograf? *

female: 47.92 %
male: 52.08 %

What is the age of people who have Type 1 diabetes when taking Prograf? *

What are other drugs people take besides Prograf? *

What are other side effects people have besides Type 1 diabetes? *

Diarrhea: 12 people, 23.53%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 9 people, 17.65%
Weight Decreased: 8 people, 15.69%
Pancreatitis (inflammation of pancreas): 8 people, 15.69%
Chronic Renal Failure (kidney failure): 7 people, 13.73%
General Physical Health Deterioration (weak health status): 7 people, 13.73%
Fever: 7 people, 13.73%
Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 7 people, 13.73%
Cytomegalovirus Infection: 7 people, 13.73%
Abdominal Pain: 6 people, 11.76%

What are the existing conditions these people have? *

Chronic Renal Failure (kidney failure): 5 people, 9.80%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 4 people, 7.84%
Phantom Pain: 2 people, 3.92%
Pain: 2 people, 3.92%
Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 2 people, 3.92%
Bipolar Disorder (mood disorder): 2 people, 3.92%
Stress And Anxiety: 2 people, 3.92%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 3.92%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 1.96%
Cystic Fibrosis (disease of the secretary glands): 1 person, 1.96%

* Approximation only. Some reports may have incomplete information.

Do you take Prograf and have Type 1 diabetes?

- Check whether Type 1 diabetes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Prograf:

Prograf (42,230 reports)

Type 1 diabetes treatments and more:

Type 1 diabetes (46,846 reports)

Browse all side effects of Prograf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Type 1 diabetes:

Type 1 diabetes (668 drugs)

Browse all the conditions that are associated with Type 1 diabetes:

Type 1 diabetes (1,644 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Prograf) and Prograf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.